News from the FDA/CDC
Latest News
FDA to step up oversight of cosmetics, assess ‘forever chemicals’
The cosmetic products include makeup products, nail polishes, shaving creams, other grooming products, perfumes, face and body cleansers, hair...
News from the FDA/CDC
FDA approves elranatamab for multiple myeloma
Elranatamab previously received Breakthrough Therapy Designation for relapsed or refractory multiple myeloma.
News from the FDA/CDC
FDA OKs combo therapy of niraparib, abiraterone acetate for prostate cancer
This new agent "brings an important treatment option to patients with prostate cancer as they consider their road ahead."
News from the FDA/CDC
FDA clears AI-assisted colonoscopy device
The device helps identify lesions in real time and is associated with a significant increase in the adenoma detection rate.
News from the FDA/CDC
FDA approves talazoparib for metastatic prostate cancer
The new approval is based on findings from the randomized, placebo-controlled, phase 3 TALAPRO-2 trial.
News from the FDA/CDC
Posluma approved for PET imaging in prostate cancer
“The study showed that Posluma PET provided clinically valuable information prior to surgery that would likely result in management changes for...
News from the FDA/CDC
New USPSTF draft suggests mammography start at 40, not 50
“It is now clear that screening every other year starting at age 40 has the potential to save about 20% more lives among all women.”
News from the FDA/CDC
Prostate cancer drug shortage leaves some with uncertainty
The therapy lutetium Lu 177 vipivotide tetraxetan will remain in limited supply until the drug’s manufacturer can ramp up production.
News from the FDA/CDC
FDA strengthens mammography regulations: Final rule
A final rule requires that mammography facilities notify patients about the density of their breasts.
News from the FDA/CDC
FDA expands abemaciclib use in high-risk early breast cancer
The new expansion removes the Ki-67 testing requirement.
News from the FDA/CDC
FDA OKs sacituzumab govitecan for HR+ metastatic breast cancer
Label expansion for the Trop-2–directed antibody-drug conjugate was based on the TROPICS-02 trial.